TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Obesity may weaken vaccine protection: study

Among those in the study without previous SARS-CoV-2 infection who had received the Pfizer vaccine, patients with severe obesity had antibody levels more than three times lower than normal-weight individuals.

News Desk (Reuters)
London, United Kingdom
Sat, May 7, 2022

Share This Article

Change Size

Obesity may weaken vaccine protection: study In this June 26, 2012 file photo, two women converse in New York. The nation's obesity epidemic continues to grow, led by an alarming increase among women. For the first time, more than 4 in 10 U.S. women are obese, according to statistics released by the Centers for Disease Control and Prevention on Tuesday, June 7, 2016. (AP Photo/Mark Lennihan)

S

evere obesity may weaken the effectiveness of COVID-19 vaccines in those who have never been infected with the coronavirus, according to a small Turkish study.

Among those in the study without previous SARS-CoV-2 infection who had received the Pfizer vaccine, patients with severe obesity had antibody levels more than three times lower than normal-weight individuals.

Among recipients of Sinovac Biotech's CoronaVac, those with severe obesity and no history of prior infection had antibody levels 27 times lower than normal weight people, according to data being presented this week at the European Congress on Obesity in Maastricht, Netherlands. By comparison, in the 70 volunteers with a previous coronavirus infection, antibody levels were similar in people with and without severe obesity.

For the study, researchers had compared immune responses to vaccines in 124 volunteers with severe obesity - defined as a body mass index of 40 or higher - and 166 normal-weight individuals (BMI less than 25). Overall, 130 participants had received two doses of the Pfizer/BioNTech mRNA vaccine and 160 had received two doses of Sinovac's inactivated-virus vaccine.

While two doses of the Pfizer/BioNTech vaccine "may generate significantly more antibodies than CoronaVac in people with severe obesity... further research is needed to determine whether these higher antibody levels provide greater protection against COVID-19," study leader Volkan Demirhan Yumuk from Istanbul University said in a statement

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.